$CKPT
Checkpoint Therapeutics, Inc.

2023 Q4 Form 10-K Financial Statement

#000141057824000283 Filed on March 22, 2024

View on sec.gov

Income Statement

Concept 2023 Q4 2023 2022
Revenue $6.000K $103.0K $192.0K
YoY Change -91.89% -46.35% -28.36%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.876M $8.685M $8.700M
YoY Change -24.42% -0.17% 1.9%
% of Gross Profit
Research & Development $8.299M $43.57M $49.83M
YoY Change -41.7% -12.56% 2.83%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $10.18M $52.25M $58.53M
YoY Change -39.14% -10.72% 2.69%
Operating Profit -$52.15M -$58.33M
YoY Change -10.6% 2.84%
Interest Expense $3.000K $84.00K $160.0K
YoY Change -95.89% -47.5% 201.89%
% of Operating Profit
Other Income/Expense, Net -$8.962M $217.0K -$4.291M
YoY Change 101.35% -105.06% -8196.23%
Pretax Income -$19.13M -$51.85M -$62.62M
YoY Change -9.01% -17.21% 10.51%
Income Tax
% Of Pretax Income
Net Earnings -$19.13M -$51.85M -$62.62M
YoY Change -9.01% -17.21% 10.51%
Net Earnings / Revenue -318800.0% -50336.89% -32616.67%
Basic Earnings Per Share -$3.17 -$7.09
Diluted Earnings Per Share -$0.70 -$2.77 -$7.09
COMMON SHARES
Basic Shares Outstanding 18.74M 8.836M
Diluted Shares Outstanding 18.74M 8.836M

Balance Sheet

Concept 2023 Q4 2023 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.928M $4.928M $12.07M
YoY Change -59.16% -59.16% -77.95%
Cash & Equivalents $4.928M $4.928M $12.07M
Short-Term Investments
Other Short-Term Assets $450.0K $450.0K $1.149M
YoY Change 516.44% -60.84% 17.73%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $5.378M $5.378M $13.29M
YoY Change -59.53% -59.53% -76.15%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $5.378M $5.378M $13.29M
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $5.378M $5.378M $13.29M
YoY Change -59.53% -59.53% -76.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $18.30M $18.30M $12.84M
YoY Change 58.65% 42.51% -20.43%
Accrued Expenses $1.206M $1.206M $1.195M
YoY Change 0.92% 0.92% 41.76%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $18.43M $18.43M $32.77M
YoY Change -43.78% -43.78% 26.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $18.43M $18.43M $32.77M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $18.43M $18.43M $32.77M
YoY Change -43.78% -43.78% 26.14%
SHAREHOLDERS EQUITY
Retained Earnings -$314.3M
YoY Change 19.73%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$13.05M -$13.05M -$19.48M
YoY Change
Total Liabilities & Shareholders Equity $5.378M $5.378M $13.29M
YoY Change -59.53% -59.53% -76.15%

Cashflow Statement

Concept 2023 Q4 2023 2022
OPERATING ACTIVITIES
Net Income -$19.13M -$51.85M -$62.62M
YoY Change -9.01% -17.21% 10.51%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$6.830M -$47.59M -$57.55M
YoY Change -55.36% -17.31% 118.79%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.990M 40.45M 14.89M
YoY Change 44.99% 171.71% -63.03%
NET CHANGE
Cash From Operating Activities -6.830M -47.59M -57.55M
Cash From Investing Activities
Cash From Financing Activities 9.990M 40.45M 14.89M
Net Change In Cash 3.160M -7.140M -42.67M
YoY Change -137.57% -83.27% -405.57%
FREE CASH FLOW
Cash From Operating Activities -$6.830M -$47.59M -$57.55M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2022 us-gaap Revenue Related Party Type Extensible Enumeration
RevenueRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023 us-gaap Revenue Related Party Type Extensible Enumeration
RevenueRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001651407
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Entity Registrant Name
EntityRegistrantName
Checkpoint Therapeutics, Inc.
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9586683
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27042035
CY2022Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2023 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-38128
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2568632
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
95 Sawyer Road
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 110
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02453
CY2023 dei City Area Code
CityAreaCode
781
CY2023 dei Local Phone Number
LocalPhoneNumber
652-4500
CY2023 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per
CY2023 dei Trading Symbol
TradingSymbol
CKPT
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
33088814
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ckpt Rule10b51 Arrangement Modified Flag
Rule10b51ArrangementModifiedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ckpt Non Rule10b51 Arrangement Modified Flag
NonRule10b51ArrangementModifiedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 dei Auditor Name
AuditorName
KPMG, LLP
CY2023 dei Auditor Location
AuditorLocation
Boston, MA
CY2023 dei Auditor Firm
AuditorFirmId
185
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4928000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12068000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
450000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1149000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
73000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
5378000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
13290000
CY2023Q4 us-gaap Assets
Assets
5378000
CY2022Q4 us-gaap Assets
Assets
13290000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
15485000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
20297000
CY2023Q4 ckpt Accounts Payable And Accrued Liabilities To Related Parties Current
AccountsPayableAndAccruedLiabilitiesToRelatedPartiesCurrent
2815000
CY2022Q4 ckpt Accounts Payable And Accrued Liabilities To Related Parties Current
AccountsPayableAndAccruedLiabilitiesToRelatedPartiesCurrent
1306000
CY2023Q4 ckpt Common Stock Warrant Liabilities Current
CommonStockWarrantLiabilitiesCurrent
125000
CY2022Q4 ckpt Common Stock Warrant Liabilities Current
CommonStockWarrantLiabilitiesCurrent
11170000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18425000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
32773000
CY2023Q4 us-gaap Liabilities
Liabilities
18425000
CY2022Q4 us-gaap Liabilities
Liabilities
32773000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27042035
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9586683
CY2023Q4 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
1492915
CY2022Q4 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
368907
CY2023Q4 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
3419000
CY2022Q4 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
1885000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
297864000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
241117000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-314333000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-262486000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-13047000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-19483000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5378000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13290000
CY2023 us-gaap Revenues
Revenues
103000
CY2022 us-gaap Revenues
Revenues
192000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43566000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
49825000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8685000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8700000
CY2023 us-gaap Operating Expenses
OperatingExpenses
52251000
CY2022 us-gaap Operating Expenses
OperatingExpenses
58525000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-52148000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-58333000
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
84000
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
160000
CY2023 ckpt Gain Loss On Common Stock Warrant Liabilities
GainLossOnCommonStockWarrantLiabilities
217000
CY2022 ckpt Gain Loss On Common Stock Warrant Liabilities
GainLossOnCommonStockWarrantLiabilities
-4451000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
301000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4291000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-51847000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-62624000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.17
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.17
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.09
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.09
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18742494
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18742494
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8835521
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8835521
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
29746000
CY2022 ckpt Stock Issued During Period Value Common Shares For At The Market Offering
StockIssuedDuringPeriodValueCommonSharesForAtTheMarketOffering
9872000
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
2924000
CY2022 ckpt Stock Issued During Period Value Common Shares For Services
StockIssuedDuringPeriodValueCommonSharesForServices
418000
CY2022 ckpt Stock Issued During Period Value Issuable For Services
StockIssuedDuringPeriodValueIssuableForServices
1885000
CY2022 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1698000
CY2022 ckpt Fractional Share Adjustment Value
FractionalShareAdjustmentValue
-6000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-62624000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-19483000
CY2023 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
2897000
CY2023 ckpt Stock Issued During Period Value Common Shares For Direct Offering
StockIssuedDuringPeriodValueCommonSharesForDirectOffering
30125000
CY2023 ckpt Stock Issued During Period Value Common Shares For Services
StockIssuedDuringPeriodValueCommonSharesForServices
952000
CY2023 ckpt Stock Issued During Period Value Issuable For Services
StockIssuedDuringPeriodValueIssuableForServices
3419000
CY2023 ckpt Stock Issued During Period Value Prefunded And Common Stock Warrants Exercised
StockIssuedDuringPeriodValuePrefundedAndCommonStockWarrantsExercised
20890000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-51847000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-13047000
CY2023 us-gaap Profit Loss
ProfitLoss
-51847000
CY2022 us-gaap Profit Loss
ProfitLoss
-62624000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
2897000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
2924000
CY2023 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
952000
CY2022 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
418000
CY2023 ckpt Common Shares Issuable Under Founder Agreement
CommonSharesIssuableUnderFounderAgreement
3419000
CY2022 ckpt Common Shares Issuable Under Founder Agreement
CommonSharesIssuableUnderFounderAgreement
1885000
CY2023 ckpt Gain Loss On Common Stock Warrant Liabilities
GainLossOnCommonStockWarrantLiabilities
217000
CY2022 ckpt Gain Loss On Common Stock Warrant Liabilities
GainLossOnCommonStockWarrantLiabilities
-4451000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-699000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
173000
CY2023 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-73000
CY2022 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
56000
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-5075000
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4622000
CY2023 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
1509000
CY2022 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
243000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-47590000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-57554000
CY2023 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0
CY2022 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1698000
CY2023 ckpt Payment For Fractional Shares Adjustment
PaymentForFractionalSharesAdjustment
0
CY2022 ckpt Payment For Fractional Shares Adjustment
PaymentForFractionalSharesAdjustment
6000
CY2023 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
11134000
CY2023 ckpt Payments Of Transactional Costs For Exercise Of Warrants
PaymentsOfTransactionalCostsForExerciseOfWarrants
1016000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
40450000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14887000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7140000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-42667000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12068000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54735000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4928000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12068000
CY2023 us-gaap Stock Issued1
StockIssued1
1885000
CY2022 us-gaap Stock Issued1
StockIssued1
6598000
CY2023 ckpt Stock Issued Under Direct Offering Costs Not Paid
StockIssuedUnderDirectOfferingCostsNotPaid
207000
CY2023 ckpt Warrant Inducement Transactional Costs Incurred But Not Paid
WarrantInducementTransactionalCostsIncurredButNotPaid
56000
CY2022Q4 ckpt Period After Mailing Of Information Statement To Common Stockholders Of Record That Reverse Stock Split Will Become Effective
PeriodAfterMailingOfInformationStatementToCommonStockholdersOfRecordThatReverseStockSplitWillBecomeEffective
P20D
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-314300000
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2022 ckpt Net Proceeds From Offering After Deducting Commissions And Other Transaction Costs
NetProceedsFromOfferingAfterDeductingCommissionsAndOtherTransactionCosts
6700000
CY2023Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
5.25
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.76
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1200000
CY2023 ckpt Adjustment Of Deemed Dividends Modification Of Existing Warrants And Issuance Of Common Stock Warrants
AdjustmentOfDeemedDividendsModificationOfExistingWarrantsAndIssuanceOfCommonStockWarrants
7500000
CY2022 ckpt Adjustment Of Deemed Dividends Modification Of Existing Warrants And Issuance Of Common Stock Warrants
AdjustmentOfDeemedDividendsModificationOfExistingWarrantsAndIssuanceOfCommonStockWarrants
0
CY2023Q4 ckpt Class Of Warrant Or Right Number Of Warrants Issued
ClassOfWarrantOrRightNumberOfWarrantsIssued
110000
CY2023Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
6215354
CY2023 ckpt Adjustment Of Deemed Dividends Modification Of Existing Warrants And Issuance Of Common Stock Warrants
AdjustmentOfDeemedDividendsModificationOfExistingWarrantsAndIssuanceOfCommonStockWarrants
7500000
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
32156675
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4064389
CY2022Q4 us-gaap Loss Contingency Accrual Carrying Value Current
LossContingencyAccrualCarryingValueCurrent
0
CY2023Q4 us-gaap Loss Contingency Accrual Carrying Value Current
LossContingencyAccrualCarryingValueCurrent
0
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 ckpt Shelf Registration Statement Maximum Authorized Securities
ShelfRegistrationStatementMaximumAuthorizedSecurities
100000000
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.33249
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7500000
CY2023Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1134000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
2400000
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
4000
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
14.20
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.037
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.029
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.835
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.731
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.01
CY2023 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
2897000
CY2022 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
2924000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.11
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.04
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.02
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.03
CY2023 ckpt Effective Income Tax Rate Reconciliation Change In State Tax Rate Percent
EffectiveIncomeTaxRateReconciliationChangeInStateTaxRatePercent
0.12
CY2022 ckpt Effective Income Tax Rate Reconciliation Change In State Tax Rate Percent
EffectiveIncomeTaxRateReconciliationChangeInStateTaxRatePercent
-0.04
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.01
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.03
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.43
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.21
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
45000000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
40456000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
1384000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
1066000
CY2023Q4 ckpt Deferred Tax Assets Amortization Of License
DeferredTaxAssetsAmortizationOfLicense
11126000
CY2022Q4 ckpt Deferred Tax Assets Amortization Of License
DeferredTaxAssetsAmortizationOfLicense
7952000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
825000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
463000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
5105000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
4112000
CY2023Q4 ckpt Deferred Tax Assets Start Up Costs
DeferredTaxAssetsStartUpCosts
24000
CY2022Q4 ckpt Deferred Tax Assets Start Up Costs
DeferredTaxAssetsStartUpCosts
21000
CY2023Q4 ckpt Deferred Tax Assets Section174 Capitalization
DeferredTaxAssetsSection174Capitalization
23793000
CY2022Q4 ckpt Deferred Tax Assets Section174 Capitalization
DeferredTaxAssetsSection174Capitalization
10671000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
87257000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
64741000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
87257000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
64741000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
87300000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
64700000
CY2023Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
1400000
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6570000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
11535000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1206000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1195000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
7123000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
7289000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
586000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
278000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
15485000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
20297000

Files In Submission

Name View Source Status
0001410578-24-000283-index-headers.html Edgar Link pending
0001410578-24-000283-index.html Edgar Link pending
0001410578-24-000283.txt Edgar Link pending
0001410578-24-000283-xbrl.zip Edgar Link pending
ckpt-20231231.xsd Edgar Link pending
ckpt-20231231x10k.htm Edgar Link pending
ckpt-20231231x10k002.jpg Edgar Link pending
ckpt-20231231xex10d122.htm Edgar Link pending
ckpt-20231231xex10d123.htm Edgar Link pending
ckpt-20231231xex23d1.htm Edgar Link pending
ckpt-20231231xex23d1001.jpg Edgar Link pending
ckpt-20231231xex31d1.htm Edgar Link pending
ckpt-20231231xex31d2.htm Edgar Link pending
ckpt-20231231xex32d1.htm Edgar Link pending
ckpt-20231231xex32d2.htm Edgar Link pending
ckpt-20231231xex4d6.htm Edgar Link pending
ckpt-20231231xex97d1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
ckpt-20231231_def.xml Edgar Link unprocessable
ckpt-20231231_lab.xml Edgar Link unprocessable
ckpt-20231231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ckpt-20231231x10k_htm.xml Edgar Link completed
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ckpt-20231231_cal.xml Edgar Link unprocessable